Jane Huang
2019 - BeiGene, Ltd.
In 2019, Jane Huang earned a total compensation of $3.6M as Chief Medical Officer, Hematology at BeiGene, Ltd., a 4% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $262,088 |
|---|---|
| Option Awards | $2,319,972 |
| Salary | $435,000 |
| Stock Awards | $579,887 |
| Other | $8,400 |
| Total | $3,605,347 |
Huang received $2.3M in option awards, accounting for 64% of the total pay in 2019.
Huang also received $262.1K in non-equity incentive plan, $435K in salary, $579.9K in stock awards and $8.4K in other compensation.
Rankings
In 2019, Jane Huang's compensation ranked 3,359th out of 13,971 executives tracked by ExecPay. In other words, Huang earned more than 76.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,359 out of 13,971 | 76th |
Division Manufacturing | 1,217 out of 5,701 | 79th |
Major group Chemicals And Allied Products | 412 out of 2,200 | 81st |
Industry group Drugs | 341 out of 1,886 | 82nd |
Industry Pharmaceutical Preparations | 255 out of 1,398 | 82nd |
Source: SEC filing on April 28, 2020.
Huang's colleagues
We found four more compensation records of executives who worked with Jane Huang at BeiGene, Ltd. in 2019.
News
Prelude Therapeutics CEO Krishna Vaddi's 2023 pay slips 20% to $2.6M
April 26, 2024
Prelude Therapeutics CEO Krishna Vaddi's 2022 pay falls 53% to $3.3M
April 28, 2023
BeiGene, Ltd. CEO John Oyler's 2019 pay falls 55% to $13M
April 28, 2020
BeiGene, Ltd. CEO John Oyler's 2018 pay jumps 171% to $28M
April 29, 2019